NS-398: Cyclooxygenase-2 independent inhibition of leukocyte priming for lipid body formation and enhanced leukotriene generation

被引:18
作者
Bozza, PT
Pacheco, P
Yu, W
Weller, PF
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Harvard Thorndike Lab,Dept Med, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Charles A Dana Res Inst,Dept Med, Boston, MA 02215 USA
[3] Inst Oswaldo Cruz, Immunopharmacol Lab, Dept Physiol & Pharmacodynam, BR-20001 Rio De Janeiro, Brazil
来源
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 2002年 / 67卷 / 04期
关键词
D O I
10.1054/plef.2002.0425
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Because the induction of new lipid body formation in leukocytes correlates with and likely contributes to their enhanced 'primed' prostaglandin and leukotriene formation, we evaluated two selective cyclooxygenase (COX)-2 inhibitors. Three types of stimuli, cis-unsaturated fatty acids, platelet activating factor and protein kinase C activators, stimulate lipid body formation. NS-398 (0.1-10 muM), but not another COX-2 inhibitor, SC58125 (0.1- 10 muM), blocked leukocyte lipid body formation elicited by all three types of stimuli and also blocked priming for enhanced LTB4 production and PGE(2) production. The effect of NS-398 on lipid body formation was independent of its inhibitory effects on COX-2 since arachidonate-induced lipid body formation in COX-2-deficient mouse leukocytes was also inhibited by NS-398. By means of its ability to inhibit leukocyte lipid body formation, NS-398 may exert actions independent of its COX-2 inhibition and more broadly contribute to the suppression of formation of COX-1 and lipoxygenase-derived eicosanoids. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:237 / 244
页数:8
相关论文
共 37 条
[1]   MODES OF ACTION OF ASPIRIN-LIKE DRUGS [J].
ABRAMSON, S ;
KORCHAK, H ;
LUDEWIG, R ;
EDELSON, H ;
HAINES, K ;
LEVIN, RI ;
HERMAN, R ;
RIDER, L ;
KIMMEL, S ;
WEISSMANN, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (21) :7227-7231
[2]  
ABRAMSON S, 1991, Current Opinion in Rheumatology, V3, P336, DOI 10.1097/00002281-199106000-00002
[3]   Eotaxins - Contributing to the diversity of eosinophil recruitment and activation [J].
Bandeira-Melo, C ;
Herbst, A ;
Weller, PF .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2001, 24 (06) :653-657
[4]   Extranuclear lipid bodies, elicited by CCR3-mediated signaling pathways, are the sites of chemokine-enhanced leukotriene C4 production in eosinophils and basophils [J].
Bandeira-Melo, C ;
Phoofolo, M ;
Weller, PF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (25) :22779-22787
[5]  
Bartemes KR, 1999, J IMMUNOL, V162, P2982
[6]   Eosinophil lipid bodies: Specific, inducible intracellular sites for enhanced eicosanoid formation [J].
Bozza, PT ;
Yu, WG ;
Penrose, JF ;
Morgan, ES ;
Dvorak, AM ;
Weller, PF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (06) :909-920
[7]   Leukocyte lipid body formation and eicosanoid generation: Cyclooxygenase-independent inhibition by aspirin [J].
Bozza, PT ;
Payne, JL ;
Morham, SG ;
Langenbach, R ;
Smithies, O ;
Weller, PF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) :11091-11096
[8]   Mechanisms of platelet-activating factor-induced lipid body formation: Requisite roles for 5-lipoxygenase and de novo protein synthesis in the compartmentalization of neutrophil lipids [J].
Bozza, PT ;
Payne, JL ;
Goulet, JL ;
Weller, PF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) :1515-1525
[9]   Arachidonyl trifluoromethyl ketone induces lipid body formation in leukocytes [J].
Bozza, PT ;
Weller, PF .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2001, 64 (4-5) :227-230
[10]   Pathways for eosinophil lipid body induction: differing signal transduction in cells from normal and hypereosinophilic subjects [J].
Bozza, PT ;
Yu, WG ;
Cassara, J ;
Weller, PF .
JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 64 (04) :563-569